Skip to content
Screener

Xencor XNCR Net Change in Cash

Net Change in Cash at other companies

Amgen logo
AmgenAMGN
$1.95B+349%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$504.6M+53.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$24.06M-13.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$51.45M-1,849%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$10.27M+142%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$14.68M-734%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Xencor’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326732-26-000043
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from the exercises of stock options9502,974
Cash paid to acquire noncontrolling interest(1,725)
Net cash provided by financing activities9501,249
Net decrease in cash, cash equivalents, and restricted cash(40,001)(1,303)
Cash, cash equivalents, and restricted cash, beginning of period54,36241,262
Cash, cash equivalents, and restricted cash, end of period$14,361$39,959
Supplemental disclosure of cash flow information
Interest paid$1$1

Item 1. Financial Statements

FAQ

What is Xencor's net change in cash?
Xencor (XNCR) reported net change in cash of -$40M in Q1 2026.
How has Xencor's net change in cash changed year-over-year?
Xencor's net change in cash decreased by 2969.9% year-over-year, from -$1.3M to -$40M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Xencor's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude